[Correlations of pharmacokinetics and pharmacodynamics of a combined preparation containing pyrrolidone and pyroglutamic acid].
Experiments showed that a new drug composition containing pyrrolidone and pyroglutamic acid exhibits a significant cerebrovascular effect upon peroral administration in rats. The pharmacokinetics of pyrrolidone monitored upon its combined administration with pyroglutamic acid shows that this drug, as a component of the composition, is characterized by a high absolute bioavailability and permeability trough the blood-brain barrier. The presence of pyroglutamic acid slows down the absorption and elimination of pyrrolidone and enhances its distribution in the organs and tissues. There is a correlation between the concentration of pyrrolidone in the brain, on the one hand, and the levels of cerebral microcirculation and arterial pressure on the other hand. An increase in the concentration of pyrrolidone in the brain is accompanied by more intensive cerebral blood flow and by a decrease in the arterial pressure.
Sariev
A K
AK
Lun'shina
E V
EV
Zherdev
V P
VP
Mirzoian
N R
NR
D000818:Animals; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects; D001812:Blood-Brain Barrier / Q000378:metabolism*; D001923:Brain Chemistry; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D008297:Male; D011760:Pyrrolidinones / Q000032:analysis / Q000493:pharmacokinetics / Q000494:pharmacology*; D011761:Pyrrolidonecarboxylic Acid / Q000032:analysis / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D011760:Pyrrolidinones; D011761:Pyrrolidonecarboxylic Acid